Sibren van den Berg

Drug Repurposing for Rare Diseases: A Role for Academia

Sibren van den Berg, Saco J. de Visser, Hubert G. M. Leufkens et al. · Frontiers in Pharmacology · 2021 · 49 citations · Full text

Pharmacy, Pharmaceutical Policy, Drug Approval Processes +16

Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia

Sibren van den Berg, Vincent van der Wel, Saco J. de Visser et al. · Value in Health · 2021 · 42 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacology +17

Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi)

Daphne H. Schoenmakers, Shanice Beerepoot, Sibren van den Berg et al. · Orphanet Journal of Rare Diseases · 2022 · 34 citations · Full text

Medicine, Internal Medicine, Neurology +13

Registries for orphan drugs: generating evidence or marketing tools?

Carla E. M. Hollak, Sandra Sirrs, Sibren van den Berg et al. · Orphanet Journal of Rare Diseases · 2020 · 28 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacology +17

Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma

Frederick W. Thielen, Renaud Heine, Sibren van den Berg et al. · Cytotherapy · 2022 · 26 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +17